NormOxys, Inc., is a biopharmaceutical company developing a technology platform for an exciting new class of small molecule drugs called oxyrens: oxygen release enhancers. Oxyrens enhance the body's ability to deliver oxygen more efficiently to all tissues that need it and offer breakthrough treatments for a wide variety of disorders, including cancer, cardiovascular diseases, anemia, stroke and diabetic retinopathy.
NormOxys’ lead product candidate, OXY111A, has demonstrated preclinical efficacy in a number of animal models, and is being concurrently developed for the treatment of congestive heart failure, cancer, and anemia. It is currently in Phase I human clinical studies.
About Us
NormOxys, Inc, was founded by Prof. Claude Nicolau, PhD, and Nobel laureate Prof. Jean-Marie Lehn, PhD, and is based on their groundbreaking scientific investigations in chemistry and cellular biophysics. The company has a strong management team with extensive experience in clinical development, R&D, and business development to successfully bring new drug products to patients.
The company is financed by a select group of private and top-tier strategic investors. The Series A financing round was led by Index Ventures, and the Series B financing round closed with Care Capital as the lead investor.
NormOxys is headquartered in Wellesley, MA, with research facilities in Boston and Strasbourg, France.